Leucid Bio Ltd announced that it has received ?11,500,000 in a round of funding co-led by new investor Vulpes Investment Management Private Ltd and returning investor Epidarex Capital on October 21, 2021. The transaction also included participation from returning investor Sofinnova Partners SAS, new investors 2invest AG and The Future Fund; a fund managed by British Business Investments Ltd. Martin Diggle from Vulpes Investment Management Private Ltd and Heikki Lanckriet from 2invest AG will join the board of directors of the company.